SynthesisLupus science & medicine2024
Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis.
Synthesis in Lupus science & medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 23 citations in OpenAlex.
- Secukinumab in active lupus nephritis: results from a phase III randomized, placebo-controlled study (SELUNE) and an open-label extension study.Rheumatology (Oxford, England) · 2026Trial
- Myocardial injury in systemic lupus erythematosus and lupus nephritis: a silent threat.Clinical kidney journal · 2026Review
- Early SLE may follow a fast comorbidity/multimorbidity trajectory associated with flare burden and glucocorticoid exposure.RMD open · 2026Article
- Clinical features and outcomes of patients with anti-neutrophil cytoplasmic antibody-positive systemic lupus erythematosus from a single-center retrospective study.Clinical rheumatology · 2026Article
- Anti-endothelin receptor A autoantibodies associate with immunovascular risk and activate endothelial signalling in SLE.Lupus science & medicine · 2026Article
- Cardiovascular disease and risk management in patients with nephrotic syndrome.Kidney research and clinical practice · 2026Article
- Reduced serum Sestrin-1 is associated with subclinical cardiovascular alterations in systemic lupus erythematosus: A controlled cross-sectional study.The Journal of international medical research · 2026Article
- Women's cardiovascular health in 2025:Saudi medical journal · 2026Review
- Recent developments in the use of biomarkers as diagnostic tools in patients with systemic lupus erythematosus: a narrative review.EULAR rheumatology open · 2026Review
- Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients With Systemic Lupus Erythematosus and Lupus Nephritis.Arthritis & rheumatology (Hoboken, N.J.) · 2026Article
- The shared genetic architecture underlying the autoimmune and cardiovascular disease: a multivariate genome-wide analysis.Cardiovascular diabetology · 2026Article
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Lupus nephritis and its association with subclinical myocardial alterations in systemic lupus erythematosus assessed by cardiovascular magnetic resonance.Frontiers in immunology · 2026Article
- Cardiovascular Disorders in Systemic Lupus Erythematosus.Current vascular pharmacology · 2026Review
- Silent Storm: Advanced Heart Failure in a Young Female Patient With Systemic Lupus Erythematosus.Cureus · 2025Article
- Article
- Total Tubulointerstitial Score: a simple and effective predictor of long-term mortality and adverse renal outcomes in lupus nephritis.Lupus science & medicine · 2025Article
- Renal arteriosclerosis in kidney biopsies associated with higher 10-year atherosclerotic cardiovascular disease in lupus nephritis.Rheumatology (Oxford, England) · 2025Article
- Intermediate monocytes in blood correlate with subclinical vascular changes in lupus nephritis.Lupus science & medicine · 2025Article
- Artificial intelligence-based cardiovascular/stroke risk stratification in women affected by autoimmune disorders: a narrative survey.Rheumatology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIt remains unclear how the presence of renal involvement will affect the cardiovascular (CV) risk factors and complications in patients with SLE.
methodsWe conducted a systematic review and meta-analysis using PubMed, EMBASE, MEDLINE and Scopus to identify studies published between 1947 and 2022 that evaluate the CV risk factors and complications in patients with SLE with or without lupus nephritis (LN).
results58 studies were evaluated, with 22 two-arm studies (n=8675) included in two-arm meta-analysis and 45 studies (n=385 315) included in proportional meta-analysis. Patients with SLE with LN showed significantly higher risk of hypertension (HT) (OR=4.93, 95% CI=3.17 to 7.65, p<0.00001, I
conclusionPatients with SLE with LN show increased risk of CV risk factors including DM, HT and hyperlipidaemia. Early identification and optimal control of these CV risk factors may reduce the risk of CV disease and other non-CV complications. PROSPERO REGISTRATION NUMBER: CRD42022314682.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.